.png?width=1999&height=767&name=Untitled%20design%20(1).png)
AMP 2025 ONCOLOGY WORKSHOP, NOW AVAILABLE ON DEMAND:
Precision Oncology in Practice: Relevance of DPYD genotyping and implementation of rapid methylation, lung and AML panels for faster results
Advancing Genomic Insights with Rapid, Targeted Analysis
Leading oncology experts Dr. Jai Patel and Dr. Laila Mnayer share how targeted genomic approaches are advancing cancer research through faster, standardized molecular profiling. In this on-demand session, they:
- Examine the relevance of analysis of the DPYD gene and the VeriDose® DPYD Panel for AMP-recommended variants in oncology research
- Explore the use of targeted panels for NSCLC and AML to enable comprehensive, scalable genomic studies
- Demonstrate how methylation analysis of MGMT and MLH1 contributes to a deeper understanding of tumor biology
- Showcase how the MassARRAY® System delivers rapid, high-quality results, accelerating translational research workflows
Learn more about the VeriDose® DPYD Panel
Explore how the VeriDose® DPYD Panel supports expanded analysis of the DPYD gene across pharmacogenomic and oncology research, enabling faster, guideline-aligned insights.
Learn moreExplore Hartford Hospital’s AMP 2025 posters showcasing real-world applications of rapid, targeted genomic panels. These studies demonstrate how laboratories are integrating MassARRAY® technology to improve efficiency, deliver faster results, and expand the depth of molecular insights across AML, NSCLC, and methylation assays.
